These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31994716)

  • 1. Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria.
    Agarwal S; Simon AR; Goel V; Habtemariam BA; Clausen VA; Kim JB; Robbie GJ
    Clin Pharmacol Ther; 2020 Jul; 108(1):63-72. PubMed ID: 31994716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
    Balwani M; Sardh E; Ventura P; Peiró PA; Rees DC; Stölzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang JD; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L;
    N Engl J Med; 2020 Jun; 382(24):2289-2301. PubMed ID: 32521132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.
    Sardh E; Harper P; Balwani M; Stein P; Rees D; Bissell DM; Desnick R; Parker C; Phillips J; Bonkovsky HL; Vassiliou D; Penz C; Chan-Daniels A; He Q; Querbes W; Fitzgerald K; Kim JB; Garg P; Vaishnaw A; Simon AR; Anderson KE
    N Engl J Med; 2019 Feb; 380(6):549-558. PubMed ID: 30726693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Givosiran: A Review in Acute Hepatic Porphyria.
    Syed YY
    Drugs; 2021 May; 81(7):841-848. PubMed ID: 33871817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.
    de Paula Brandão PR; Titze-de-Almeida SS; Titze-de-Almeida R
    Mol Diagn Ther; 2020 Feb; 24(1):61-68. PubMed ID: 31792921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved
    Li J; Liu J; Zhang X; Clausen V; Tran C; Arciprete M; Wang Q; Rocca C; Guan LH; Zhang G; Najarian D; Xu Y; Smith P; Wu JT; Chong S
    Drug Metab Dispos; 2021 Jul; 49(7):572-580. PubMed ID: 33941543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.
    Ventura P; Bonkovsky HL; Gouya L; Aguilera-Peiró P; Montgomery Bissell D; Stein PE; Balwani M; Anderson DKE; Parker C; Kuter DJ; Monroy S; Oh J; Ritchie B; Ko JJ; Hua Z; Sweetser MT; Sardh E;
    Liver Int; 2022 Jan; 42(1):161-172. PubMed ID: 34717041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Givosiran: First Approval.
    Scott LJ
    Drugs; 2020 Feb; 80(3):335-339. PubMed ID: 32034693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
    Sardh E; Harper P
    J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
    Vassiliou D; Sardh E; Harper P; Simon AR; Clausen VA; Najafian N; Robbie GJ; Agarwal S
    Clin Pharmacol Ther; 2021 Nov; 110(5):1250-1260. PubMed ID: 34510420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.
    Sardh E; Rejkjaer L; Andersson DE; Harper P
    Clin Pharmacokinet; 2007; 46(4):335-49. PubMed ID: 17375984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.
    Wang B; Bonkovsky HL; Lim JK; Balwani M
    Gastroenterology; 2023 Mar; 164(3):484-491. PubMed ID: 36642627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recovery of chronic motor neuropathy due to acute intermittent porphyria after givosiran treatment in a young boy: a case report.
    Mazzoli M; Ricci A; Vaudano AE; Marcacci M; Marchini S; Bergonzini P; Di Pierro E; Pischik E; Iughetti L; Pietrangelo A; Meletti S; Ventura P
    Eur Rev Med Pharmacol Sci; 2024 Apr; 28(8):3268-3274. PubMed ID: 38708485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Givosiran to treat acute porphyria.
    Honor A; Rudnick SR; Bonkovsky HL
    Drugs Today (Barc); 2021 Jan; 57(1):47-59. PubMed ID: 33594389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic model of urinary δ-aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria.
    Lee J; Melch M; Robbie GJ
    CPT Pharmacometrics Syst Pharmacol; 2023 Jun; 12(6):842-852. PubMed ID: 36883675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normal reference ranges for urinary δ-aminolevulinic acid and porphobilinogen levels.
    Agarwal S; Habtemarium B; Xu Y; Simon AR; Kim JB; Robbie GJ
    JIMD Rep; 2021 Jan; 57(1):85-93. PubMed ID: 33473344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial.
    Kuter DJ; Bonkovsky HL; Monroy S; Ross G; Guillén-Navarro E; Cappellini MD; Minder AE; Hother-Nielsen O; Ventura P; Jia G; Sweetser MT; Thapar M;
    J Hepatol; 2023 Nov; 79(5):1150-1158. PubMed ID: 37479139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Givosiran for the treatment of acute hepatic porphyria.
    Ricci A; Ventura P
    Expert Rev Clin Pharmacol; 2022 Apr; 15(4):383-393. PubMed ID: 35531651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.
    Wang B; Ventura P; Takase KI; Thapar M; Cassiman D; Kubisch I; Liu S; Sweetser MT; Balwani M
    Orphanet J Rare Dis; 2022 Aug; 17(1):327. PubMed ID: 36028858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Givosiran in acute intermittent porphyria: A personalized medicine approach.
    Poli A; Schmitt C; Moulouel B; Mirmiran A; Talbi N; Rivière S; Cerutti D; Bouchoule I; Faivre A; Grobost V; Douillard C; Duchêne F; Fiorentino V; Dupré T; Manceau H; Peoc'h K; Puy H; Lefebvre T; Gouya L
    Mol Genet Metab; 2022 Mar; 135(3):206-214. PubMed ID: 35058124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.